Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Amgen Signs Chinese Partner for Vectibix

In an effort to commercialize its colorectal cancer therapy Vectibix in China, biotech Amgen (NASDAQ: AMGN  ) will form a joint venture with Zhejiang Beta Pharma to capitalize on its strong expertise in the development and commercialization of molecularly targeted therapies as well as its oncology sales network in China, the company announced this week.

The new joint venture will be named Amgen-Beta Pharmaceuticals Co., Ltd. with Zhejiang Beta Pharma owning 51% and Amgen owning the remaining 49% interest.

"This joint venture brings us one step closer to providing Chinese patients with Amgen's medicines and supports our strategy of expanding in key, fast-growing markets," said Amgen Executive VP Anthony C. Hooper.

Zhejiang Beta Pharma Chairman Lieming Ding was quoted as saying "Amgen is a pioneer and a global leader in the biotech industry. Our partnership with Amgen will be of long-term strategic significance not only for Zhejiang Province, but also for the whole medical community in China."

The joint venture is subject to closing conditions, including the approval of government authorities in China. Amgen had U.S. sales of Vectibix of $27 million last quarter, down 13%, while sales elsewhere in the world were up 2% at $60 million.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2423471, ~/Articles/ArticleHandler.aspx, 4/1/2015 9:24:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Rich Duprey

Rich has been a Fool since 1998 and writing for the site since 2004. After 20 years of patrolling the mean streets of suburbia, he hung up his badge and gun to take up a pen full time.

Having made the streets safe for Truth, Justice and Krispy Kreme donuts, he now patrols the markets looking for companies he can lock up as long-term holdings in a portfolio. So follow me on Facebook and Twitter for the most important industry news in retail and consumer products and other great stories.


Today's Market

updated 12 hours ago Sponsored by:
DOW 17,776.12 -200.19 0.00%
S&P 500 2,067.89 -18.35 0.00%
NASD 4,900.89 -46.56 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/31/2015 3:59 PM
AMGN $159.85 Down -4.46 +0.00%
Amgen, Inc. CAPS Rating: ****